Dror Harats
31Patents
14h-index
16Co-inventors
74Inventor score
Filing activity: Feb 28, 1995 → Jul 18, 2013
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6838452B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | Emerging Cross-Sectional Technologies | 31 | Expired |
| US7504388B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | Emerging Cross-Sectional Technologies | 25 | Active |
| US7902176B2 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | Emerging Cross-Sectional Technologies | 25 | Expired |
| US7067649B2 | Promoters exhibiting endothelial cell specificity and methods of using same | Chemistry; Metallurgy | 24 | Expired |
| US7186704B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | Emerging Cross-Sectional Technologies | 24 | Expired |
| US7973023B2 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | Emerging Cross-Sectional Technologies | 24 | Active |
| US7625882B2 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | Emerging Cross-Sectional Technologies | 24 | Active |
| US7893291B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | Emerging Cross-Sectional Technologies | 21 | Active |
| US5747340A | Targeted gene expression using preproendothelin-1 promoters | Chemistry; Metallurgy | 20 | Expired |
| US7585666B2 | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy | Chemistry; Metallurgy | 19 | Expired |
| US8158611B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | Emerging Cross-Sectional Technologies | 14 | Active |
| US7989427B2 | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy | Chemistry; Metallurgy | 14 | Active |
| US7579327B2 | Promoters exhibiting endothelial cell specificity and methods of using same | Chemistry; Metallurgy | 14 | Expired |
| US8039261B2 | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis | Chemistry; Metallurgy | 14 | Active |
| US8415318B2 | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy | Chemistry; Metallurgy | 12 | Active |
| US8206743B2 | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis | Chemistry; Metallurgy | 12 | Active |
| US8071740B2 | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis | Chemistry; Metallurgy | 12 | Expired |
| US8563534B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | Emerging Cross-Sectional Technologies | 6 | Active |
| US8835398B2 | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis | Chemistry; Metallurgy | 6 | Active |
| US8501715B2 | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders | Emerging Cross-Sectional Technologies | 6 | Active |
| US8846401B2 | Promoters exhibiting endothelial cell specificity and methods of using same | Chemistry; Metallurgy | 5 | Active |
| US8859747B2 | Promoters exhibiting endothelial cell specificity and methods of using same | Chemistry; Metallurgy | 5 | Active |
| US8859745B2 | Promoters exhibiting endothelial cell specificity and methods of using same | Chemistry; Metallurgy | 5 | Active |
| US8916378B2 | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulations of angiogenesis and anticancer therapy | Chemistry; Metallurgy | 4 | Active |
| US7264813B2 | Therapeutic uses of Dunaliella powder | Human Necessities | 3 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.